Inhibition of microsomal glucose-6-phosphate transport in human neutrophils results in apoptosis: A potential explanation for neutrophil dysfunction in glycogen storage disease type 1b

Blood

Volumn 101, Issue 6, 2003, Pages 2381-2387

  Leuzzi, Rosanna ^b   Bánhegyi, Gábor ^b   Kardon, Tamás ^b   Marcolongo, Paola ^b   Capecchi, Piero Leopoldo ^b   Burger, Hans Joerg ^b   Benedetti, Angelo ^a   Fulceri, Rosella ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; ANTIOXIDANT; CHLOROGENIC ACID; GLUCOSE 6 PHOSPHATE; N ETHYLMALEIMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXIDOREDUCTASE; PHORBOL 13 ACETATE 12 MYRISTATE; SUPEROXIDE;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROTECTION; CELL TRANSPORT; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GENE MUTATION; GLUCOSE HOMEOSTASIS; GLYCOGEN STORAGE DISEASE TYPE 1; HUMAN; HUMAN CELL; LEUKOCYTE; LIVER FUNCTION; LIVER MICROSOME; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL;

EID: 0037443499     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2576     Document Type: Article

References (59)

1. Ashmore J, Weber G. The role of hepatic glucose-6-phosphatase in the regulation of carbohydrate metabolism. Vitam Horm. 1959;17:91-132.
2. van Schaftingen E, Gerin I. The glucose-6-phosphatase system. Biochem J. 2002;362:513-532.
3. Arion WJ, Lange AJ, Walls HE, Ballas LM. Evidence for the participation of independent translocases for phosphate and glucose-6-phosphate in the microsomal glucose-6-phosphatase system. J Biol Chem. 1980;255:10396-10406.
4. Lei KJ, Shelly LL, Pan CJ, Sidbury JB, Chou JY. Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a. Science. 1993;262:580-583.
5. Gerin I, Veiga-da-Cunha M, Achouri Y, Collet JF, van Schaftingen E. Sequence of a putative glucose-6-phosphate translocase, mutated in glycogen storage disease type 1b. FEBS Lett. 1997;419:235-238.
6. Cori GT, Cori CF. Glucose-6-phosphatase of the liver in glycogen storage disease. J Biol Chem. 1952;199:661-667.
7. Chen YT, Burchell A. Glycogen storage diseases. In: The metabolic basis of inherited disease. Scriver CR, Beaudet AL, Sly WS, and Valle D, eds. New York, NY: McGraw-Hill. 1995;935-965.
8. Lei KJ, Pan CJ, Shelly LL, Liu JL, Chou JY. Identification of mutations in the gene for glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type 1a. J Clin Invest. 1994;93:1994-1999.
9. Galli L, OrricoA, Marcolongo P. Mutations in the glucose-6-phosphate transporter (G6PT) gene in patients with glycogen storage disease type 1b and 1c. FEBS Lett. 1999;459:255-258.
10. Gerin I, Veiga-da-Cunha M, Nol G, van Schaftingen E. Structure of the gene mutated in glycogen storage disease type 1b. Gene. 1999;227:189-195.
11. Hiraiwa H, Pan CJ, Lin B, Moses SW, Chou JY. Inactivation of the glucose-6-phosphate transporter causes glycogen storage disease type 1b. J Biol Chem. 1999;274:5532-5536.
12. Marcolongo P, Barone V, Priori G, et al. Structure and mutation analysis of the glycogen storage disease type 1b gene. FEBS Lett. 1998;436:247-250.
13. Veiga-da-Cunha M, Gerin I, Chen YT, et al. The putative glucose-6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type 1 non-a. Eur J Hum Gen. 1999;7:717-723.
14. Calderwood S, Kilpatrick L, Douglas SD, et al. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood. 2001;97:376-382.
15. Ambruso DR, McCabe ERB, Anderson D, et al. Infections and bleeding complications in patients with glycogenosis 1B. Am J Dis Child. 1985;139: 691-697.
16. Beaudet AL, Anderson DC, Michels VV, Arion WJ, Lange AJ. Neutropenia and impaired neutrophil migration in type 1b glycogen storage disease. J Pediatr. 1980;97:906-910.
17. Kilpatrick L, Garty BZ, Lundquist KF, et al. Impaired metabolic function and signaling defects in phagocytic cells in glycogen storage disease type 1b. J Clin Invest. 1990;86:196-202.
18. Verhoeven AJ, Visser G, Van Zwieten R, Gruszczynska B, Tien Poll-The DWE, Smit GPA. A convenient diagnostic function test of peripheral blood neutrophils in glycogen storage disease type 1b. Pediatr Res. 1999;45:881-885.
19. Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type 1b: results of the European Study on glycogen storage disease type 1. J Pediatr, 2000;137:187-191.
20. Bashan N, Potashnik R, Peist A, Peleg N, Moran A, Moses SW. Deficient glucose phosphorylation as a possible common denominator and its relation to abnormal leukocyte function, in glycogen storage disease 1b patients. Eur J Pediatr. 1993;152(suppl 1):S44-S48.
21. Korchak HM, Garty BZ, Stanley CA, Baker L, Douglas SD, Kitpatrick L. Impairment of calcium mobitization in phagocytic cells in glycogen storage disease type 1b. Eur J Pediatr. 1993;152(suppl 1):S39-S43.
22. Potashnik R, Moran A, Moses SW, Peleg N, Bashan N. Hexose uptake and transport in polymorphonuclear leukocytes from patients with glycogen storage disease 1b. Pediatr Res, 1990;28:19-23.
23. Chen PY, Csutora P, Veyna-Burke NA, Marchase RB. Glucose-6-phosphate and Ca2+ sequestration are mutually enhanced in microsomes from liver, brain, and heart. Diabetes. 1998;47:874-881.
24. Arion WJ, Canfield WK, Ramos FC, et al. Chlorogenic acid analogue S3483: a potent competitive inhibitor of the hepatic and renal glucose-6-phosphatase systems. Arch Biochem Biophys. 1998;351:279-285.
25. Hjorth R, Jonsson AK, Vretblad P. A rapid method for purification of human granulocytes using percoll: a comparison with dextran sedimentation, J Immunol Methods. 1981;43:95-101.
26. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med. 1979;149:969-974.
27. Sumimoto J, Takeshige K, Minakami S. Characterization of human neutrophil leukotriene B4 omega-hydroxylase as a system involving a unique cytochrome P-450 and NADPH-cytochrome P-450 reductase. Eur J Biochem. 1988;172:315-324.
28. Bánhegyi G, Marcolongo P, Fulceri R, Hinds C, Burchell A, Benedetti A. Demonstration of a metabolically active glucose-6-phosphate pool in the lumen of liver microsomal vesicles. J Biol Chem. 1997;272:13584-13590.
29. Leuzzi R, Fulceri R, Marcolongo P, et al. Glucose-6-phosphate transport in fibroblast microsomes from glycogen storage disease type 1b patients: evidence for multiple glucose-6-phosphate transport systems. Biochem J. 2001;357:557-562.
30. Markert M, Andrews PC, Babior BM. Measurement of O2-production by human neutrophils. The preparation and assay of NADPH oxidase-containing particles from human neutrophils. Methods Enzymol. 1984;105:358-365.
31. Bromberg Y, Pick E. Activation of NADPH-dependent superoxide production in a cell-free system by sodium dodecyl sulfate. J Biol Chem. 1985;260:13539-13545.
32. 2- pool is sensitive to both inositol 1,4,5-trisphosphate and thapsigargin. Cell Calcium. 1995;17:431-441.
33. Fulceri R, Bellomo G, Gamberucci A, Scott HM, Burchell A, Benedetti A. Permeability of rat liver microsomal membrane to glucose 6-phosphate. Biochem J. 1992;286:813-817.
34. Clottes E, Burchell A. Three thiol groups are important for the activity of the liver microsomal glucose-6-phosphatase system. Unusual behavior of one thiol located in the glucose-6-phosphate translocase. J Biol Chem. 1998;273:19391-19397.
35. Bánhegyi G, Marcolongo P, Burchell A, Benedetti A. Heterogeneity of glucose transport in rat liver microsomal vesicles. Arch Biochem Biophys. 1998;359:133-138.
36. Bandsma RH, Wiegman CH, Herling AW, et al. Acute inhibition of glucose-6-phosphate translocator activity leads to increased de novo lipogenesis and development of hepatic steatosis without affecting VLDL production in rats. Diabetes. 2001;50:2591-2597.
37. Herling AW, Burger HJ, Schwab D, Hemmerle H, Below P, Schubert G. Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system. Am J Physiol. 1998;274:G1087-G1093.
38. van Dijk TH, van der Sluijs FH, Wiegman CH, et al. Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats. A pharmacological study with the chlorogenic acid derivative S4048. J Biol Chem. 2001;276:25727-25735.
39. McCawtey LJ, Korchak HM, Douglas SD, et al. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization. Pediatr Res. 1994;35:84-90.
40. Gamberucci A, Marcolongo P, Fulceri R, et al. Low levels of glucose-6-phosphate hydrolysis in the sarcoplasmic reticulum of skeletal muscle: involvement of glucose-6-phosphatase. Mol Membr Biol. 1996;13:103-108.
41. Khan A, Ling ZC, Pukk K, Herling AW, Landau BR, Efendic S. Effects of 3-mercaptopicolinic acid and a derivative of chlorogenic acid (S-3483) on hepatic and islet glucose-6-phosphatase activity. Eur J Pharmacol. 1998;349:325-331.
42. Calderwood S, Kilpatrick L, Douglas SD. Recombinant human granulocyte colony stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease 1b. Blood. 2001;97:376-382.
43. Vera JC, Rivas CI, Zhang RH, Golde DW. Colony-stimulating factors signal for increased transport of vitamin C in human host defense cells. Blood. 1998;91:2536-2546.
44. Fadeel B, Ahlin A, Henter J-I, Orrenius S, Hampton MB. Involvement of caspases in neutrophil apoptosis: regulation by reactive oxygen species. Blood. 1998;92:4808-4818.
45. Akgul C, Moulding DA, Edwards SW. Molecular control of neutrophil apoptosis. FEBS Lett. 2000;487:318-322.
46. Watson RW. Redox regulation of neutrophil apoptosis. Antioxid Redox Signal. 2002;4:97-104.
47. Bublitz C, Lawler CA, Steavenson S. The topology of phosphogluconate dehydrogenases in rat liver microsomes. Arch Biochem Biophys. 1987;259:22-28.
48. Bublitz C, Steavenson S. The pentose phosphate pathway in the endoplasmic reticulum. J Biol Chem. 1988;263:12849-12853.
49. Takahashi T, Hori SH. Alterations in the latency of hepatic microsomal hexose-6-phosphate dehydrogenase under various in vivo and in vitro conditions. Biochim Biophys Acta. 1981;672:165-175.
50. Hino J, Minakami S. Hexose-6-phosphate and 6-phosphogluconate dehydrogenases of rat liver microsomes. Involvement in NADPH and carbon dioxide generation in the luminal space of microsomal vesicles. J Biochem (Tokyo). 1982;92:547-557.
51. Bublitz C, Lawler CA. The levels of nicotinamide nucleotides in liver microsomes and their possible significance to the function of hexose phosphate dehydrogenase. Biochem J. 1987;245:263-267.
52. Gerin I, Noel G, van Schaftingen E. Novel arguments in favor of the substrate-transport model of glucose-6-phosphatase. Diabetes. 2001;50:1531-1538.
53. Gerin I, Van Schaftingen E. Evidence for glucose-6-phosphate transport in rat liver microsomes. FEBS Lett. 2002;517:257-260.
54. Barash V, Erlich T, Bashan N. Microsomal hexose-6-phosphate and 6-phosphogluconate dehydrogenases in extrahepatic tissues: human placenta and pig kidney cortex. Biochem Int. 1990;20:267-274.
55. Myzak MC, Carr AC. Myeloperoxidase-dependent caspase-3 activation and apoptosis in HL-60 cells: protection by the antioxidants ascorbate and (dihydro)lipoic acid. Redox Rep. 2002;7:47-53.
56. Guaiquil VH, Vera JC, Golde DW. Mechanism of vitamin C inhibition of cell death induced by oxidative stress in glutathione-depleted HL-60 cells. J Biol Chem. 2001;276:40955-40961.
57. Clark RA, Li SL, Pearson DW, et al. Regulation of calreticulin expression during induction of differentiation in human myeloid cells: evidence for remodeling of the endoplasmic reticulum. J Biol Chem. 2002;277:32369-32378.
58. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20536 high risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23-33.
59. Schwab D, Herling AW, Hemmerle H, Schubert G, Hagenbuch B, Burger HJ. Hepatic uptake of synthetic chlorogenic acid derivatives by the organic anion transport proteins. J Pharmacol Exp Ther. 2001;296:91-98.